or Try an Advanced Search...

    Technical Analysis for KALA - Kala Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 6.59 -3.23% -0.22
    KALA closed down 3.23 percent on Friday, April 19, 2024, on 38 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: May 7
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical KALA trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness -3.23%
    Inside Day Range Contraction -3.23%
    Down 3 Days in a Row Weakness -3.23%
    Down 4 Days in a Row Weakness -3.23%
    Older End-of-Day Signals for KALA ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 15 hours ago
    Fell Below Lower Bollinger Band about 15 hours ago
    Fell Below Previous Day's Low about 20 hours ago
    Down 2 % about 20 hours ago
    Down 1% about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    KALA Chart by TradingView
    Basic chart:

    Profile

    Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Pain Eye Inflammation Ophthalmic Macular Degeneration Tyrosine Kinase Retina Wet Age Related Macular Degeneration Glucocorticoids Receptor Tyrosine Kinase Retinal Disease Blepharitis Post Surgical Ocular Inflammation

    Is KALA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 29 Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44
    Mar 29 KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Feb 26 KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
    Feb 6 KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
    Nov 13 Kala Pharmaceuticals GAAP EPS of -$3.41 misses by $1.26
    Nov 13 KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
    See more KALA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 19.31
    52 Week Low 5.1
    Average Volume 19,917
    200-Day Moving Average 9.03
    50-Day Moving Average 7.43
    20-Day Moving Average 7.48
    10-Day Moving Average 7.09
    Average True Range 0.31
    RSI (14) 24.24
    ADX 29.96
    +DI 9.45
    -DI 27.30
    Chandelier Exit (Long, 3 ATRs) 7.20
    Chandelier Exit (Short, 3 ATRs) 7.35
    Upper Bollinger Bands 8.39
    Lower Bollinger Band 6.57
    Percent B (%b) 0.01
    BandWidth 24.39
    MACD Line -0.23
    MACD Signal Line -0.10
    MACD Histogram -0.1215
    Fundamentals Value
    Market Cap 17.75 Million
    Num Shares 2.69 Million
    EPS -22.38
    Price-to-Earnings (P/E) Ratio -0.29
    Price-to-Sales 1.16
    Price-to-Book 1.77
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.19
    Resistance 3 (R3) 7.20 7.02 7.09
    Resistance 2 (R2) 7.02 6.86 7.01 7.06
    Resistance 1 (R1) 6.80 6.77 6.71 6.79 7.02
    Pivot Point 6.62 6.62 6.57 6.61 6.62
    Support 1 (S1) 6.40 6.46 6.31 6.39 6.16
    Support 2 (S2) 6.22 6.37 6.21 6.12
    Support 3 (S3) 6.00 6.22 6.09
    Support 4 (S4) 5.99